Monoclonal hybridoma and corresponding antibody

Details Monoclonal hybridoma and corresponding antibody Monoclonal hybridoma and corresponding antibody

A - Human Necessities

61

K

167/129, 195/1.1

A61K 39/395 (2006.01) C07K 16/30 (2006.01) C12N 5/00 (2006.01) C12P 21/00 (2006.01) A61K 38/00 (2006.01)

Patent

CA 1276119

ABSTRACT The invention concerns a novel lymphocyte hybridoma and an antibody which may be generated from the hybridoma. The hybridoma and antibody have the internal designation LICR-LON-Fib 75. The origin, method of preparation and uses are discussed. The antibody has particular application in the diagnosis and treatment of cancer of the breast. A particular therapeutic treatment comprises harvesting a sample of bone marrow from a patient, subjecting the patient to treatment adapted to kill cancerous material including that within the bone marrow (possibly including the normal differentiated haemopoietic cells of the marrow), subjecting some or all of the sample to cytotoxic treatment with the antibody (or a toxin conjugate thereof) adapted to kill cancerous cell lines while leaving viable colony-forming units of bone marrow, and reintroducing the treated sample material to the blood stream of the patient.

442217

Affiliated with

Also associated with

Rating

Monoclonal hybridoma and corresponding antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal hybridoma and corresponding antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal hybridoma and corresponding antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1328984